This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

reputable news agency

proofread

In utero stimulant exposure not tied to later neurodevelopmental issues

In utero rx stimulant exposure not tied to later neurodevelopmental issues

Amphetamine/dextroamphetamine and methylphenidate exposure in utero does not appear to increase the risk for childhood neurodevelopmental disorders, according to a study published online Jan. 24 in JAMA Psychiatry.

Elizabeth A. Suarez, Ph.D., M.P.H., from Brigham and Women's Hospital in Boston, and colleagues evaluated the association between childhood neurodevelopmental disorders and in utero exposure to stimulant medications for attention-deficit/ (ADHD). The analysis included health care utilization data from publicly insured (Medicaid data from 2000 to 2018) and commercially insured (MarketScan Commercial Claims Database data from 2003 to 2020) pregnant individuals aged 12 to 55 years.

The researchers found that when adjusting for measured confounders, /dextroamphetamine exposure was not associated with any outcome (: hazard ratio [HR], 0.80 [95% confidence interval (CI), 0.56 to 1.14]; ADHD: HR, 1.07 [95% CI, 0.89 to 1.28]; any neurodevelopmental disorder: HR, 0.91 [95% CI, 0.81 to 1.28]). There was an association seen between methylphenidate exposure and an increased risk for ADHD (HR, 1.43; 95% CI, 1.12 to 1.82) but not other outcomes after adjustment (autism spectrum disorder: HR, 1.06 [95% CI, 0.62 to 1.81]; any neurodevelopmental disorder: HR, 1.15 [95% CI, 0.97 to 1.36]). With stricter control for confounding by maternal ADHD, the association between methylphenidate and ADHD did not persist.

"Given the recent rise in use of stimulant medications for ADHD in adults and during , these results are reassuring for patients who depend on these medications throughout pregnancy for control of debilitating ADHD symptoms that interfere with daily functioning," the authors write.

More information: Elizabeth A. Suarez et al, Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children, JAMA Psychiatry (2024). DOI: 10.1001/jamapsychiatry.2023.5073

Journal information: JAMA Psychiatry

2024 HealthDay. All rights reserved.

Citation: In utero stimulant exposure not tied to later neurodevelopmental issues (2024, February 1) retrieved 23 April 2024 from https://medicalxpress.com/news/2024-02-utero-exposure-neurodevelopmental-issues.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Sleep disorders found to differ for autism, ADHD versus typical development

1 shares

Feedback to editors